Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ICCM

Icecure Medical Ltd

Dec 08 • 10:57AM ET

0.6799

-0.0064 -0.94 %

Healthcare • Medical Devices • Israel • NASD

Peers: BMRN NBIX ANIK BLFS CRIS OSUR QURE TGTX VRTX XBIT

Index	-	P/E	-	EPS (ttm)	-0.26	Insider Own	41.31%	Shs Outstand	68.96M	Perf Week	-4.92%
Market Cap	46.71M	Forward P/E	-	EPS next Y	-0.14	Insider Trans	0.00%	Shs Float	40.31M	Perf Month	-1.84%
Enterprise Value	36.99M	PEG	-	EPS next Q	-0.04	Inst Own	0.43%	Short Float	2.99%	Perf Quarter	-33.99%
Income	-15.29M	P/S	15.67	EPS this Y	26.96%	Inst Trans	6.86%	Short Ratio	1.02	Perf Half Y	-33.37%
Sales	2.98M	P/B	5.04	EPS next Y	32.56%	ROA	-100.74%	Short Interest	1.21M	Perf YTD	-37.00%
Book/sh	0.13	P/C	4.67	EPS next 5Y	38.05%	ROE	-157.91%	52W High	1.63 -58.25%	Perf Year	-15.50%
Cash/sh	0.15	P/FCF	-	EPS past 3/5Y	4.59% 2.44%	ROIC	-163.88%	52W Low	0.59 15.25%	Perf 3Y	-35.24%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-7.35% 15.36%	Gross Margin	35.06%	Volatility	4.47% 6.53%	Perf 5Y	-50.50%
Dividend TTM	-	EV/Sales	12.41	EPS Y/Y TTM	8.98%	Oper. Margin	-517.75%	ATR (14)	0.04	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.90	Sales Y/Y TTM	-18.96%	Profit Margin	-513.95%	RSI (14)	39.70	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.38	EPS Q/Q	25.54%	SMA20	-2.76%	Beta	1.12	Target Price	3.12
Payout	-	Debt/Eq	0.03	Sales Q/Q	28.40%	SMA50	-13.57%	Rel Volume	0.33	Prev Close	0.69
Employees	72	LT Debt/Eq	0.00	Earnings	Nov 19 BMO	SMA200	-31.86%	Avg Volume	1.18M	Price	0.68
IPO	Nov 07, 2013	Option/Short	No / Yes	EPS/Sales Surpr.	-20.00% 19.05%	Trades		Volume	101,568	Change	-0.94%

Dec-05-25 08:30AM	IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes (PR Newswire)
Nov-26-25 08:00PM	Icecure Medical Ltd (ICCM) Q3 2025 Earnings Call Highlights: Navigating Challenges and ... (GuruFocus.com)
Nov-19-25 08:54AM	IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025 (PR Newswire)
Nov-18-25 08:30AM	IceCure's ProSense Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer (PR Newswire)
07:19AM	Icecure Medical Ltd (ICCM) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
04:30PM	Loading…
Nov-14-25 04:30PM	IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification (PR Newswire)
Nov-12-25 08:30AM	IceCure Medical to Report Third Quarter 2025 Financial and Operating Results on November 19, 2025 (PR Newswire)
Nov-10-25 08:30AM	IceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction (PR Newswire)
Nov-06-25 08:15AM	Viatris (VTRS) Beats Q3 Earnings and Revenue Estimates (Zacks)
Nov-05-25 07:00PM	Acadia Healthcare (ACHC) Beats Q3 Earnings and Revenue Estimates (Zacks)
Nov-03-25 08:30AM	IceCure's Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival (PR Newswire)
Oct-13-25 08:30AM	IceCure's ProSense Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances (PR Newswire)
Oct-09-25 08:30AM	IceCure Medical to Attend the 2025 Maxim Growth Summit (PR Newswire)
Oct-06-25 10:16AM	ICCM Shares Rise as FDA Clears ProSense for Breast Cancer Treatment (Zacks)
Oct-03-25 12:28PM	IceCure Medical's ProSense Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care (PR Newswire)
12:19PM	Loading…
12:19PM	IceCure Receives FDA Marketing Authorization for ProSense Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above (PR Newswire)
Sep-30-25 08:30AM	IceCure's ProSense at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies Presented (PR Newswire)
Sep-22-25 08:30AM	IceCure's ProSense Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented (PR Newswire)
Sep-18-25 08:30AM	IceCure Granted Notice of Allowance for U.S. Patent for its Next-Generation XSense Cryoprobes (PR Newswire)
Sep-16-25 12:29PM	Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals (PR Newswire) -5.56%
Sep-15-25 08:30AM	IceCure Receives Regulatory Approval in Israel for its Next-Generation XSense Cryoablation System for Breast Cancer and Other Indications (PR Newswire) +9.59%
Sep-08-25 08:30AM	Two New Publications from the Independent THERMAC Trial Featuring IceCure's ProSense in Breast Cancer Finds 95% of Patients Satisfied with Thermal Ablation; ProSense Cryoablation Achieves Highest Complete Ablation Rate (PR Newswire)
Sep-04-25 08:30AM	IceCure's ProSense Substantially Reduces Abdominal Wall Endometriosis Pain with High Procedural Efficacy (PR Newswire)
Aug-14-25 03:12AM	Icecure Medical Ltd (ICCM) (H1 2025) Earnings Call Highlights: Navigating Challenges and ... (GuruFocus.com)
Aug-13-25 09:40AM	IceCure Medical Ltd. (ICCM) Q2 Earnings Surpass Estimates (Zacks)
08:30AM	IceCure Reports Financial & Operational Results for the First Half of 2025 (PR Newswire)
Aug-12-25 09:39AM	Icecure Medical Ltd (ICCM) Q2 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Aug-07-25 08:05AM	Viatris (VTRS) Tops Q2 Earnings and Revenue Estimates (Zacks)
Aug-06-25 08:30AM	IceCure to Report First Half 2025 Financial and Operating Results on August 13, 2025 (PR Newswire)
Jul-29-25 09:00AM	IceCure Announces Expiration and Results of Approximately Two Times Over-Subscribed Rights Offering for Aggregate Gross Proceeds of $10.0 Million (PR Newswire)
10:30AM	Loading…
Jul-25-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +8.63%
09:00AM	IceCure's ProSense Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation (PR Newswire)
Jul-24-25 09:00AM	IceCure Reminds Shareholders of Upcoming Expiration of Rights Offering Subscription Period (PR Newswire)
08:00AM	Labcorp Holdings (LH) Q2 Earnings and Revenues Top Estimates (Zacks)
Jul-10-25 08:00AM	IceCure Announces Commencement of Rights Offering (PR Newswire)
Jul-03-25 08:30AM	IceCure Reports Preliminary Financial Results for the Three and Six Months Ended June 30, 2025 (PR Newswire)
Jun-25-25 09:23AM	IceCure Announces Record Date for Rights Offering for Up to $10 Million (PR Newswire)
Jun-09-25 08:30AM	IceCure Receives Notice of Patent Allowance in U.S. for a Novel Cryogen Flow Control to Optimize Patient Outcomes (PR Newswire)
May-29-25 07:00PM	Icecure Medical Ltd (ICCM) Q1 2025 Earnings Call Highlights: Strategic Advances and Market ... (GuruFocus.com)
May-28-25 08:30AM	IceCure Medical Reports First Quarter 2025 Financial Results (PR Newswire) -8.85%
May-27-25 09:22AM	Icecure Medical Ltd (ICCM) Q1 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com) +6.60%
May-21-25 08:30AM	IceCure to Report First Quarter 2025 Financial & Operational Results on May 28, 2025 (PR Newswire)
May-12-25 05:05PM	Ascend Wellness Holdings, Inc. (AAWH) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -5.83% +6.87%
May-08-25 05:55PM	Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-06-25 08:30AM	IceCure Receives High Level of Interest from Breast Surgeons at ASBrS 2025 Annual Meeting Following Recent Positive FDA Development on ProSense Cryoablation (PR Newswire)
Apr-30-25 08:30AM	IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense Cryoablation in Women 70+ with Early-Stage Breast Cancer (PR Newswire)
Apr-28-25 08:30AM	IceCure Exhibits ProSense & Sponsors Breast Cryoablation Courses at the Society of Breast Imaging Symposium (PR Newswire)
Apr-22-25 08:30AM	IceCure's ProSense Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation (PR Newswire)
Mar-28-25 09:16AM	IceCure Medical Stock Dips Despite Positive ICESECRET Study Results (Zacks)
Mar-27-25 01:45PM	IceCure Medical Ltd (ICCM) Q4 2024 Earnings Call Transcript (SeekingAlpha)
08:30AM	IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense Cryoablation Sales in North America (PR Newswire)
Mar-24-25 08:30AM	IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate (PR Newswire)
Mar-21-25 08:30AM	IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025 (PR Newswire)
Mar-20-25 11:02AM	IceCure tumbles after updating plans to seek FDA nod for ProSense (SeekingAlpha) -15.54%
08:30AM	IceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense Cryoablation in Early-Stage Breast Cancer (PR Newswire)
Mar-18-25 08:30AM	IceCure's ProSense Cryoablation Featured in Six Studies Presented at St. Gallen International Breast Cancer Conference (PR Newswire)
Mar-17-25 08:30AM	IceCure Receives Notice of Allowance in China for Novel Cryogenic Pump for Next-Generation Cryoablation Technology (PR Newswire) +7.04%
Mar-10-25 08:30AM	Breast Cancer Patients who Underwent IceCure's ProSense Cryoablation in Japan Reported Significantly Higher Satisfaction than Patients who Underwent Standard of Care Surgery (PR Newswire)
Feb-25-25 07:15AM	IceCure seeks Israeli regulatory approval for XSense cryoablation system (Medical Device Network)
Feb-24-25 08:30AM	IceCure Submits Filing for Regulatory Approval of its Next-Generation XSense Cryoablation System in Israel (PR Newswire)
Feb-04-25 08:30AM	IceCure's ProSense in the Spotlight at Society of Interventional Oncology (SIO) Annual Meeting: Award Winning Abstract and Hands-On Training for Breast Cryoablation as Medical Community Anticipates FDA's Market Authorization Decision (PR Newswire)
Jan-28-25 07:43AM	IceCure submits application to Chinas NMPA for cryoablation system approval (Medical Device Network)
Jan-27-25 08:30AM	IceCure Files for Regulatory Approval of ProSense Cryoablation System in China (PR Newswire)
Jan-13-25 07:00AM	IceCure Medical CEO Issues Letter to Shareholders and Reports Increase of 42% in ProSense Sales for 2024 in North America (PR Newswire) -9.96%
07:00AM	IceCure Medical CEO Issues Letter to Shareholders & Reports Increase of 42% in ProSense® Sales for 2024 in North America (PR Newswire)
Jan-06-25 08:30AM	IceCure Medical Regains Full Nasdaq Compliance with Nasdaq Minimum Closing Bid Price Rule (PR Newswire) +5.38%
Jan-03-25 08:30AM	European Patent Office Issues Intention to Grant Notice to IceCure for its Next-Generation Cryoablation Technology (PR Newswire) +5.69%
Dec-16-24 08:30AM	Data on IceCure's ProSense Cryoablation for Low-Risk Breast Cancer Presented at Radiological Society of North America's 2024 Annual Meeting (PR Newswire)
Dec-05-24 08:30AM	IceCure's ProSense Cryoablation Safe and Effective in Destruction of Kidney Tumors with 88.7% Recurrence-Free Rate Based on Interim ICESECRET Study Results (PR Newswire)
Nov-26-24 09:40AM	IceCure Medical Ltd. (ICCM) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
08:30AM	IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense Cryoablation (PR Newswire)
Nov-25-24 08:30AM	IceCure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance from Japan's Patent Office (PR Newswire) +9.13%
Nov-20-24 08:30AM	IceCure Medical to Report Third Quarter 2024 Financial and Operational Results on November 26, 2024 (PR Newswire)
08:30AM	IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024 (PR Newswire)
Nov-19-24 08:30AM	IceCure's ProSense Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health (PR Newswire)
Nov-11-24 06:35AM	IceCures cryoablation system for breast cancer treatment gains FDA panel support (Medical Device Network) -6.77%
Nov-08-24 07:00AM	FDA Advisory Panel Votes in Favor of IceCure's ProSense Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast Cancer (PR Newswire) -11.73%
Oct-29-24 08:30AM	Upcoming FDA Advisory Panel for IceCure's ProSense Marketing Authorization Receives Large Number of Public Comments from Stakeholders (PR Newswire) +18.18%
Oct-21-24 08:30AM	IceCure Receives Notice of Allowance from U.S. Patent and Trademark Office for its Next-Generation Cryoablation System (PR Newswire) +7.50%
Oct-07-24 08:15AM	IceCure's ProSense Featured in 6 Global Studies on Cryoablation of Breast Tumors at the 2024 European Society of Breast Imaging Conference (PR Newswire)
Sep-24-24 08:15AM	IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free Rate (PR Newswire)
Sep-16-24 08:00AM	Study Published in the British Journal of Radiology Demonstrates IceCure's ProSense is a Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of the Lung, Bone, and Soft Tissues (PR Newswire)
Sep-12-24 08:00AM	IceCure Announces FDA Advisory Panel Meeting Date for Marketing Authorization of ProSense in Early-Stage Low Risk Breast Cancer Scheduled for November 7, 2024 (PR Newswire)
Sep-04-24 08:30AM	IceCure to Meet Institutional Investors at the H.C. Wainwright and Lake Street Capital Markets Conferences (PR Newswire)
Aug-28-24 08:30AM	USPTO Grants Notice of Allowance for Additional Patent on IceCure's Novel Cryogenic Pump Technology: Reinforces IceCure's Global IP Leadership in Cryoablation Technologies (PR Newswire) -5.42%
Aug-20-24 12:52PM	ICCM Stock Earnings: Icecure Medical Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace) +18.18%
09:40AM	IceCure Medical Ltd. (ICCM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
08:30AM	IceCure Medical Reports 20% Growth in ProSense System and Probe Sales for the First Half of 2024; Reflects Continued Adoption in the U.S. and Other Global Markets (PR Newswire)
Aug-14-24 08:30AM	IceCure's ProSense Destroyed 100% of Breast Cancer Tumors in Independent Study of Patients Who Chose Cryoablation Instead of Surgery (PR Newswire)
Aug-13-24 08:30AM	IceCure Medical to Report Second Quarter 2024 Financial & Operational Results on August 20, 2024 (PR Newswire)
Aug-07-24 08:30AM	IceCure Announces Positive Data from the Largest Multi-Institutional Study of its Kind: 'Cryoablation of Primary Breast Cancer in Patients Ineligible for Clinical Trials' (PR Newswire)
Jul-22-24 11:53AM	IceCure presents hat-trick of positive trial data for cryoablation device (Medical Device Network) -6.66%
08:30AM	99.74% Recurrence Free Rate for Women with Breast Cancer Treated with IceCure's ProSense Cryoablation System: Key Findings Delivered at 32nd Annual Meeting of the Japanese Breast Cancer Society (PR Newswire)
04:52AM	IceCure Medical receives Nasdaq compliance notice (Medical Device Network)
Jul-19-24 04:30PM	IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification (PR Newswire)
Jul-11-24 01:22PM	IceCure's (ICCM) ProSense Breast Cancer Study Meets Endpoint (Zacks)
Jul-09-24 08:30AM	European Study Provides More Evidence Supporting IceCure's ProSense is Safe & Effective Cryoablation Treatment for Metastatic and Recurrent Breast Cancer (PR Newswire)
Jul-03-24 11:50AM	IceCure Medical (ICCM) New Cryoablation System Gets FDA Nod (Zacks)
Jul-02-24 05:52AM	FDA grants marketing authorisation for IceCures XSense Cryoablation System (Medical Device Network)
Jul-01-24 08:30AM	U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense Cryoablation System with CryoProbes (PR Newswire)

IceCure Medical Ltd. engages in the development and marketing of therapy for the treatment of tumors. Its product, ProSense Cryoablation System, provides invasive treatment option to destroy tumors by freezing them. The company was founded in 2006 and is headquartered in Caesarea, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ICCM

Icecure Medical Ltd

Upgrade your FINVIZ experience